Why are physicians not prescribing diuretics more frequently in the management of hypertension?

JAMA

Volumn 279, Issue 22, 1998, Pages 1813-1816

  Moser, Marvin ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; PLACEBO;

CHOLESTEROL METABOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIURETIC THERAPY; DRUG CHOICE; DRUG INDICATION; DRUG MARKETING; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; META ANALYSIS; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0032503682     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.22.1813     Document Type: Review

References (55)

1. Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
2. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;165:829-837.
3. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA. 1996;275:1577-1580.
4. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA. 1997;278: 1745-1748.
5. Moser M, Blaufox MD, Freis E, et al. Who really determines your patients' prescriptions? JAMA. 1991;265:498-500.
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-883.
7. Hebert P, Moser M, Mayer J, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
8. Houston NC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J. 1989;117: 911-949.
9. Zusman RM. Alternatives to traditional antihypertensive therapy. Hypertension. 1986;8:837-842.
10. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA. 1988;259:2118-2122.
11. MRFIT Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:1765-1801.
12. Moser M. Diuretics and cardiovascular risk factors. Eur Heart J. 1992;13(suppl G):72-80.
13. Ames RP. The effect of antihypertensive drugs on serum lipids and lipoproteins, 1:diuretics. Drugs. 1986;32:260-278.
14. Moser M. Suppositions and speculations - their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118: 1362-1369.
15. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-724.
16. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo, result of a Department of Veterans Affairs Cooperative Study. N Engl J Med. 1993;328:914-921.
17. Middeke M, Weisweiler P, Schwandt P, Holzgreve H. Serum lipoprotein during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial. Clin Cardiol. 1987;10:94-98.
18. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 1993;21:335-343.
19. Langford HG. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986;29 (suppl 1, pt 3):29-54.
20. Savage PJ, Pressel S, Curb D, et al. Influence of long term, low dose, diuretic based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension on the Elderly Program. Arch Intern Med. 1988;158: 741-751.
21. Shapiro AP, Benedik TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. N Engl J Med. 1961;265:1028-1033.
22. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
23. Moser M. Current hypertension management: separating fact from fiction. Cleve Clin J Med. 1993; 60:27-37.
24. Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care. 1993;16:542-547.
25. Lasser NL, Grandits MA, Gaggiula AW. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52-66.
26. Greenberg G, Brennen PJ, Mian WE, et al. Effects of diuretic and beta blocker therapy in the Medical Research Council Trial. Am J Med. 1984; 76:45-51.
27. Gurwitz GH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1993;118:273-278.
28. Curb JD, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Advantage of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276: 1886-1892.
29. McInnes GT, Yeo WW, Ramsay LE, Moser M. Cardiotoxicity and diuretics: much speculation -little substance. J Hypertens. 1992;10:317-335.
30. Moser M. Diuretics as first-step therapy in hypertension. In: Mann RD, Guarino RA, eds. Chlorthalidone 25 mg. Lancaster, England: MTP Press Ltd; 1979:13-25.
31. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results: Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-1477.
32. Moser M. Clinical trials and their effect on medical therapy: the Multiple Risk Factor Intervention Trial. Am Heart J. 1984;107:616-618.
33. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
34. Holland OB, Nixon JV, Kuhnert I. Diuretic-induced ventricular ectopic activity. Am J Med. 1981; 770:762-768.
35. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand. 1981;647(suppl):67-73.
36. Papademetriou V, Burns JF, Notargiacomo A, Fletcher RD, Freis ED. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med. 1988;148:1272-1276.
37. Medical Research Council Working Party on Mild to Moderate Hypertension. Ventricular extrasystoles during thiazide treatment: sub-study of MRC mild hypertension trial. BMJ. 1983;287:1249-1253.
38. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330: 1852-1857.
39. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995;123: 481-487.
40. Moser M, Gifford RW. Diuretic therapy and the risk of cardiac arrest. N Engl J Med. 1994;331:1235-1236.
41. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
42. Epstein M. Calcium antagonists should continue to be used as first-line treatment of hypertension. Arch Intern Med. 1995;155:2150-2156.
43. Messerli FH, Nunez BD, Nunez NM, et al. Hypertension and sudden death: disparate effects of calcium entry blockers and diuretic therapy on cardiac dysrhythmias. Arch Intern Med. 1989;149:1263-1267.
44. Moser M, Setaro J. Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics. Eur Heart J. 1991;12:1034-1039.
45. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation. 1997;95:2007-2014.
46. Moser M, Hebert P. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in the hypertension treatment trials. J. Am Coll Cardiol. 1996;27:1214-1218.
47. Oglivie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian Hypertension Society Consensus Conference, 3: pharmacologic treatment of essential hypertension. Can Med Assoc J. 1993;149:575-584.
48. Hypertension Guidelines Committee, South Australian Faculty, Royal Australian College of General Practitioners. Hypertension: Diagnosis, Treatment and Maintenance: Guidelines Endorsed by the High Blood Pressure Research Council of Australia. Adelaide South Australian Faculty, Royal Australian College of General Practitioners; 1991.
49. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993 World Health Organization-International Society of Hypertension guidelines for the management of mild hypertension. BMJ. 1993;307:1541-1546.
50. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-987.
51. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA. 1996;276:785-791.
52. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997;350: 757-764.
53. The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
54. Lewis EJ, Hunsicker LG, Bain RP, et al, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
55. Grimm RH, Grandits GA, Cutler JA, et al. Relationship of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997; 157:638-648.